Arbaclofen placarbil clinical trials
How each study uses arbaclofen placarbil is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- arbaclofen placarbil
- 2
Studies by the year they started
5 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 1 |
| 2011 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses arbaclofen placarbil is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord InjuryCompletedPhase 2XenoPort, Inc.NCT00557973Written as XP19986 SR1, 10 mg BIDHow we know
- Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple SclerosisCompletedPhase 3XenoPort, Inc.NCT01359566Written as Arbaclofen placarbil 15 mg BIDHow we know
- An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERDCompletedPhase 2XenoPort, Inc.NCT00557401Written as XP19986 SR3, 20 mg QDHow we know
- A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back SpasmsCompletedPhase 2XenoPort, Inc.NCT00817986Written as Arbaclofen placarbil, 20 mgHow we know
- A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use DisorderCompletedPhase 2Indivior Inc.NCT02511886Written as Arbaclofen PlacarbilHow we know
As the comparator · 1 — what is tested is compared with arbaclofen placarbil
Codes
What other systems call arbaclofen placarbil · ClinicalTrials.gg INT005493
- MeSH (NLM) C543531arbaclofen placarbilConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) W89H91R7VXARBACLOFEN PLACARBILConfirmed FDA, NLM, Wikidata
- Wikidata Q15408425arbaclofen placarbilConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76088Arbaclofen PlacarbilOne source FDA
- DrugBank DB08892One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C543531 | arbaclofen placarbil | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | W89H91R7VX | ARBACLOFEN PLACARBIL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q15408425 | arbaclofen placarbil | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76088 | Arbaclofen Placarbil | One source FDA |
| DrugBank | DB08892 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.